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Abstract 
Bacterial secondary metabolites are low molecular mass compounds, which are not essential 
for bacterial growth. These secondary metabolites are produced in the stationary phase of 
bacterial growth and the produced compounds could have a variety of biological functions. One 
of these functions are the antibiotic or antimicrobial function that is gaining interest in the 
microbial community recently. 
In this work Gram-negative bacterial strains were cultivated, and their produced secondary 
metabolites were extracted and tested in antimicrobial plate assays against Gram-positive and 
Gram-negative bacterial strains as well. The well-known antibiotic, pyrrolnitrin content of the 
extracts were also determined by HPLC-Quadrupole-Orbitrap MS. 
 
Introduction 
Bacterial secondary metabolites are low molecular mass compounds, which are not essential 
for bacterial growth. They provide many different biological functions for bacteria in nature 
[1]. There are many compounds that can be considered as secondary metabolites from bacterial 
sources such as antibiotics [2], enzymes inhibitors [3] and growth promoters [4]. These types 
of metabolites are produced during the stationary phase of bacterial growth. 
Natural antibiotics are compounds that are produced by certain types of bacteria as secondary 
metabolites [5]. They began to take a wide range of interest especially in the medical and 
microbiological fields [6,7]. 
 
Experimental 
Five bacterial strains (Serratia marcescens, SZMC 0567; Serratia plymuthica, SZMC 24063; 
Pseudomonas chlororaphis, SZMC 24067; S. plymuthica, SZMC 24069; S. plymuthica, SZMC 
24070) were collected from the Szeged Microbial Collection (SZMC). 
Strains were cultivated on three different media to get the antimicrobial effects of their 
secondary metabolites tested. The three media were Czapek-Dox broth (CzDb), glutamate-
nitrate medium (GNM) and glutamate-nitrate medium completed with D-tryptophan 
(GNM+Trp). 
Grown cultures were centrifuged and the supernatant was extracted with ethyl-acetate. Organic 
phases were dried over MgSO4 and were filtered as well as evaporated. 
Gained crude extracts were redissolved in 10% methanol (in water (v/v%)) and were 
centrifuged to get rid of the precipitate. With the solutions antimicrobial microplate assays were 
performed against three Gram-positive and three Gram-negative bacteria, to get their 
antimicrobial properties determined. After 24h of incubation, inhibitory rates were calculated. 
The pyrrolnitrin content of the crude extracts was determined by HPLC-Quadrupole-Orbitrap 
MS. 1 mg of each crude extract was redissolved in 1 ml MS grade methanol and was injected 
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to the HPLC-QOMS. The pyrrolnitrin content was determined by ESTD calibration in the range 
of 25-500 ng/ml concentration. 
 
Results and discussion 
After successful cultivation of the five bacterial strains in three different media the fermentation 
material was extracted by ethyl-acetate. The antimicrobial activity of the crude extracts was 
tested against Gram-positive (Bacillus subtilis, Micrococcus luteus and Saphylococcus aureus) 
and Gram-negative (Eserichia coli, S. marcescens and Pseudomonas aeruginosa) bacteria as 
well. The experiments resulted that the extracts were active against Gram-positive bacteria and 
were no growth inhibition against Gram-negative ones. The samples were most active against 
B. subtilis and less active in the cases of M. luteus and S. aureus. There were two of the 
cultivated bacteria that might produce high concentrations of antimicrobial agents, because 
when the extract was in contact with B. subtilis inhibitory rates reached above 80%. These 
bacteria were S. plymuthica (SZMC 24063) grown on CzDb and GNM media and S. 
plymuthica, (SZMC 24069) grown on CzDb. 
For further investigation a well-known antibiotic compound, the concentration pyrrolnitrin was 
determined in the crude samples by HPLC-Quadrupole-Orbitrap MS. External standard 
calibration was carried out in the range of 25-500 ng/ml concentration. It was found that S. 
plymuthica (SZMC 24069) grown on CzDb produced high concentrations of pyrrolnitrin (1687 
ng/ml) and S. plymuthica, (SZMC 24070) grown on GNM+Trp (868 ng/ml). The pyrrolnitrin 
production of SZMC 24069 can be correlated to the antimicrobial plate assay, this high 




Cultivation of five bacterial strains on three culture media was carried out. The secondary 
metabolites were successfully extracted from the liquid media. The antimicrobial activity of the 
crude extracts was tested against Gram-positive and Gram-negative bacteria. 
It can be concluded that two bacteria had produced secondary metabolites on certain culture 
media that are effective against Gram-positive bacteria. The pyrrolnitrin concentrations were 
also determined by HPLC-Quadrupole-Orbitrap MS , and in one case, the antimicrobial activity 
can be correlated to the measured high concentration of pyrrolnitrin. 
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